{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:07:47Z","timestamp":1761919667241},"reference-count":15,"publisher":"Societas Neurologica Japonica","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rinsho Shinkeigaku"],"published-print":{"date-parts":[[2013]]},"DOI":"10.5692\/clinicalneurol.53.19","type":"journal-article","created":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T22:56:53Z","timestamp":1358377013000},"page":"19-23","source":"Crossref","is-referenced-by-count":5,"title":["Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon \u03b2-1b therapy"],"prefix":"10.5692","volume":"53","author":[{"given":"Kensuke","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Ohsawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Furutera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3663","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Paty D, Li D. Interferon beta-1b is effective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS\/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662-667.","DOI":"10.1212\/WNL.43.4.662"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655-661.","DOI":"10.1212\/WNL.43.4.655"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Saida T, Tashiro K, Itoyama Y, et al. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005; 64: 621-630.","DOI":"10.1212\/01.WNL.0000151856.10387.E2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Saida T, Itoyama Y, Tashiro K, et al. Intramuscular interferon beta-1a is effective in Japanese patients with relapsingremitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhance MRI brain lesions. Mult Scler 2012 Apr 4 Epub.","DOI":"10.1177\/1352458512442261"},{"key":"5","unstructured":"5) Gotsman I, Elhallel-Darnitski M, Friedlander Z, et al. Betainterferon-induced nephrotic syndrome in a patient with multiple sclerosis. Clin Nephrol 2000; 54: 425-426."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tola M, Caniatti L, Gragnaniello D, et al. Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a. J Neurol 2003; 250: 768-769.","DOI":"10.1007\/s00415-003-1090-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Auty A, Saleh A. Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a. Can J Neurol Sci 2005; 32: 366-368.","DOI":"10.1017\/S0317167100004303"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9) Henderson R, Saltissi D, Pender M. Goodpasture\u2019s syndrome associated with multiple sclerosis. Acta Neurol Scand 1998; 98: 134-135.","DOI":"10.1111\/j.1600-0404.1998.tb01733.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10) Campos A, Gieron M, Gunasakeran S, et al. Membranous nephropathy associated with multiple sclerosis. Pediatr Neurol 1993; 9: 64-66.","DOI":"10.1016\/0887-8994(93)90014-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11) Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 2008; 3: 905-919.","DOI":"10.2215\/CJN.04321007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12) Markowitz G, Nasr S, Stokes M, et al. Treatment with IFN-\u03b1, -\u03b2, or -\u03b3 is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010; 5: 607-615.","DOI":"10.2215\/CJN.07311009"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13) Dimitrov Y, Heibel F, Marcellin L, et al. Acute renal failure and nephrotic syndrome with alpha interferon therapy. Nephrol Dial Transplant 1997; 12: 200-203.","DOI":"10.1093\/ndt\/12.1.200"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14) Izzedine H, Launay-Vacher V, Bourry E, et al. Drug-induced glomerulopathies. Expert Opin Drug Saf 2006; 5: 95-106.","DOI":"10.1517\/14740338.5.1.95"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15) Hall C, Fothergill N, Blackwell M, et al. The natural course of gold nephropathy: long term study of 21 patients. Br Med J (Clin Res Ed) 1987; 295: 745-748.","DOI":"10.1136\/bmj.295.6601.745"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16) Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106: 13S-24S.","DOI":"10.1016\/S0002-9343(99)00113-8"}],"container-title":["Rinsho Shinkeigaku"],"original-title":["\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3\u03b2-1b \u9577\u671f\u6cbb\u7642\u4e2d\u306b\u30cd\u30d5\u30ed\u30fc\u30bc\u75c7\u5019\u7fa4\u3092\u5408\u4f75\u3057\u305f\u591a\u767a\u6027\u786c\u5316\u75c7\u306e 2 \u4f8b"],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T20:06:21Z","timestamp":1621541181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/clinicalneurol\/53\/1\/53_19\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.5692\/clinicalneurol.53.19","relation":{},"ISSN":["0009-918X","1882-0654"],"issn-type":[{"value":"0009-918X","type":"print"},{"value":"1882-0654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}